Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Monitoring of carcinoembryonic antigen levels is predictive of EGFR mutations and efficacy of EGFR-TKI in patients with lung adenocarcinoma.

Zhang Y, Jin B, Shao M, Dong Y, Lou Y, Huang A, Han B.

Tumour Biol. 2014 May;35(5):4921-8. doi: 10.1007/s13277-014-1646-1. Epub 2014 Jan 24.

PMID:
24459065
2.

Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma.

Li H, Wang Y, Su F, Li J, Gong P.

Int J Clin Exp Pathol. 2015 May 1;8(5):5577-83. eCollection 2015.

4.

Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations.

Gao Y, Song P, Li H, Jia H, Zhang B.

BMC Cancer. 2017 Jul 14;17(1):484. doi: 10.1186/s12885-017-3474-3.

5.

Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.

Tanaka K, Hata A, Kaji R, Fujita S, Otoshi T, Fujimoto D, Kawamura T, Tamai K, Takeshita J, Matsumoto T, Monden K, Nagata K, Otsuka K, Nakagawa A, Tachikawa R, Otsuka K, Tomii K, Katakami N.

J Thorac Oncol. 2013 Jul;8(7):892-8. doi: 10.1097/JTO.0b013e31828c3929.

6.

Serum carcinoembryonic antigen levels predicts the efficacy of EGFR-TKI in non-small cell lung cancer harboring EGFR mutations.

Yanwei Z, Bo J, Yuqing L, Rong L, Xueyan Z, Song H, Baohui H.

J Cancer Res Ther. 2016 Jan-Mar;12(1):254-8. doi: 10.4103/0973-1482.153666.

7.

EGFR mutation status in plasma and tumor tissues in non-small cell lung cancer serves as a predictor of response to EGFR-TKI treatment.

Que D, Xiao H, Zhao B, Zhang X, Wang Q, Xiao H, Wang G.

Cancer Biol Ther. 2016;17(3):320-7. doi: 10.1080/15384047.2016.1139238. Epub 2016 Jan 19.

8.

Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.

Yu JY, Yu SF, Wang SH, Bai H, Zhao J, An TT, Duan JC, Wang J.

Chin J Cancer. 2016 Mar 21;35:30. doi: 10.1186/s40880-016-0086-2.

9.

Value of ¹⁸F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma.

Ko KH, Hsu HH, Huang TW, Gao HW, Shen DH, Chang WC, Hsu YC, Chang TH, Chu CM, Ho CL, Chang H.

Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1889-97. doi: 10.1007/s00259-014-2802-y. Epub 2014 May 23. Erratum in: Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1989-90.

PMID:
24852187
10.

Concurrence of EGFR amplification and sensitizing mutations indicate a better survival benefit from EGFR-TKI therapy in lung adenocarcinoma patients.

Shan L, Wang Z, Guo L, Sun H, Qiu T, Ling Y, Li W, Li L, Liu X, Zheng B, Lu N, Ying J.

Lung Cancer. 2015 Sep;89(3):337-42. doi: 10.1016/j.lungcan.2015.06.008. Epub 2015 Jun 19.

PMID:
26141217
11.

[Value of carcinoembryonic antigen levels in predicting the efficacy of EGFR-TKI in advanced non-small cell lung cancer harboring EGFR mutations].

Jin B, Zhang Y, Zhang X, Li R, Lou Y, Niu Y, Huang A, Han B.

Zhonghua Yi Xue Za Zhi. 2014 Aug 13;94(30):2327-31. Chinese.

PMID:
25399971
12.

Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.

Seki Y, Fujiwara Y, Kohno T, Takai E, Sunami K, Goto Y, Horinouchi H, Kanda S, Nokihara H, Watanabe S, Ichikawa H, Yamamoto N, Kuwano K, Ohe Y.

Oncologist. 2016 Feb;21(2):156-64. doi: 10.1634/theoncologist.2015-0288. Epub 2016 Jan 14.

14.

Correlation between EGFR mutations and serum tumor markers in lung adenocarcinoma patients.

Pan JB, Hou YH, Zhang GJ.

Asian Pac J Cancer Prev. 2013;14(2):695-700.

15.

Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients.

Tseng YH, Tseng YC, Lin YH, Lee YC, Perng RP, Whang-Peng J, Chen YM.

Oncologist. 2015 Jul;20(7):758-66. doi: 10.1634/theoncologist.2014-0352. Epub 2015 Jun 8.

16.

A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?

Lv C, An C, Feng Q, Ma Y, Li S, Wang J, Zhang J, Wang X, Yan S, Fang J, Wang Y, Tan F, Yang Y.

Clin Lung Cancer. 2015 Nov;16(6):e173-81. doi: 10.1016/j.cllc.2015.04.002. Epub 2015 Apr 20.

17.

Correlation between serum CEA levels and EGFR mutations in Chinese nonsmokers with lung adenocarcinoma.

Jin B, Dong Y, Wang HM, Huang JS, Han BH.

Acta Pharmacol Sin. 2014 Mar;35(3):373-80. doi: 10.1038/aps.2013.164. Epub 2014 Feb 3.

18.

Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.

Han JY, Kim SH, Lee YS, Lee SY, Hwang JA, Kim JY, Yoon SJ, Lee GK.

Lung Cancer. 2014 Aug;85(2):161-7. doi: 10.1016/j.lungcan.2014.04.009. Epub 2014 Apr 29.

PMID:
24857785
19.

Advanced lung adenocarcinoma harboring a mutation of the epidermal growth factor receptor: CT findings after tyrosine kinase inhibitor therapy.

Choi CM, Kim MY, Lee JC, Kim HJ.

Radiology. 2014 Feb;270(2):574-82. doi: 10.1148/radiol.13121824. Epub 2013 Oct 28.

PMID:
24086072
20.

[Correlation between Serum Tumor Markers and Efficacy of First-line EGFR-TKIs in Patients with Advanced Lung Adenocarcinoma].

Chen H, Yang X, Liu H, Ma K, Zhong J, Dong Z, Zhuo M, Wang Y, Li J, An T, Wu M, Wang Z, Zhao J.

Zhongguo Fei Ai Za Zhi. 2017 Sep 20;20(9):589-597. doi: 10.3779/j.issn.1009-3419.2017.09.01. Chinese.

Supplemental Content

Support Center